Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 34021
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BI 34021 is an investigational drug developed as an oral drinking solution, studied for its safety, tolerability, and pharmacokinetics in healthy male volunteers at dose ranges from 5 to 500 mg. The available information does not specify the mechanism of action or therapeutic indication. It is being evaluated in early-phase clinical studies and no further details on its molecular target or disease focus are currently public.
- Brand names
- BI-34021 FU2BI34021 FU2BI 34021 FU2
- Other names
- BI 34021 FU2BI34021 FU2BI-34021 FU2
Beyond the preview
Go deeper on BI 34021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 34021.